Boston Scientific Sinks 9% as Weak Guidance Spooks Investors

Edgen Stock

·Mar 30 2026, 23:22

Share to

Share to

Copy link

Key Takeaways

Boston Scientific shares extended their recent slide, falling sharply as investors continue to penalize the company for a weaker-than-expected outlook despite solid historical performance. The stock's significant underperformance relative to the broader market highlights growing concerns over its near-term growth trajectory.

Price Collapse: Boston Scientific (BSX) stock closed down 9.02% at $62.93 on March 30, hitting a new 52-week low and extending its year-to-date loss to 27.5%.
Guidance Disappoints: The negative sentiment stems from management's Q1 forecast, which fell short of expectations and triggered a 17.6% stock drop after its February 4 earnings report, overshadowing strong Q4 results.
Contrasting Outlooks: Despite the stock's poor performance, analysts maintain a positive long-term view, projecting 12.8% earnings per share growth for fiscal 2026.

BSX Plunges 9% to a New 52-Week Low

Boston Scientific (BSX) shares tumbled 9.02% on March 30, closing at $62.93 and marking a new 52-week low for the medical device maker. The drop extends a significant downturn for the stock, which has fallen 27.5% year-to-date. This performance starkly contrasts with the broader market; over the past 52 weeks, BSX has declined 31.4%, while the S&P 500 Index gained 11.9% and the Health Care Select Sector SPDR ETF (XLV) slipped only 1.2%.

Weak Guidance Overwhelms Strong Q4 Results

The sell-off is rooted in investor reaction to the company's forward-looking guidance rather than its past performance. The downturn was initially triggered after its fourth-quarter results were released on February 4, which caused the stock to fall 17.6%. Operationally, the quarter was strong, with net sales increasing 15.9% year-over-year to $5.3 billion and adjusted EPS rising 14.3% to $0.80, beating analyst estimates. However, management’s guidance for the first quarter came in below Wall Street expectations, shifting investor focus to near-term uncertainty and away from the solid quarterly execution.

Analysts Project 12.8% EPS Growth Despite Headwinds

Despite the market's bearish sentiment, Wall Street analysts project a robust long-term financial picture for Boston Scientific. The consensus forecast for fiscal year 2026, ending in December, anticipates a profit of $3.45 per share, representing a 12.8% increase from fiscal 2025. Furthermore, earnings per share are expected to grow another 13% in fiscal 2027 to $3.90. This optimistic long-term view clashes with the stock's current trajectory, which has placed it among a handful of healthcare and consumer stocks hitting new lows in a volatile market.